The publication preferred product characteristics (PPC) for therapeutic TB vaccines provides guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. It includes potential clinical end-points for evidence generation and discusses key considerations about potential clinical development strategies. You can read the article here.
